Tapentadol extended-release (ER), an investigational drug, was associated with better gastrointestinal tolerability in elderly patients with moderate-to-severe chronic pain, with fewer discontinuing the study due to treatment-emergent adverse events (TEAEs) than oxycodone controlled-release (CR), investigators concluded in a presentation during the 29th Annual Scientific Meeting of the American Pain Society.
Interested in Monitoring? Call 877-596-2224
Current Customers Call 877-296-6465
Patients & Other Questions Call 877-643-6179